PBIG.F Stock Overview
Engages in the research and development of therapeutic products for human use in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Paradigm Biopharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.19 |
| 52 Week High | AU$0.67 |
| 52 Week Low | AU$0.16 |
| Beta | 1.02 |
| 11 Month Change | 0% |
| 3 Month Change | -14.18% |
| 1 Year Change | -69.24% |
| 33 Year Change | -88.05% |
| 5 Year Change | -81.19% |
| Change since IPO | -81.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBIG.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -1.4% | 1.8% |
| 1Y | -69.2% | 10.5% | 24.2% |
Return vs Industry: PBIG.F underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: PBIG.F underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| PBIG.F volatility | |
|---|---|
| PBIG.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PBIG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PBIG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Paul Rennie | www.paradigmbiopharma.com |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited Fundamentals Summary
| PBIG.F fundamental statistics | |
|---|---|
| Market cap | US$68.61m |
| Earnings (TTM) | -US$46.59m |
| Revenue (TTM) | US$28.39k |
2,416x
P/S Ratio-1.5x
P/E RatioIs PBIG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBIG.F income statement (TTM) | |
|---|---|
| Revenue | AU$42.05k |
| Cost of Revenue | AU$11.47k |
| Gross Profit | AU$30.58k |
| Other Expenses | AU$69.03m |
| Earnings | -AU$69.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 72.73% |
| Net Profit Margin | -164,092.68% |
| Debt/Equity Ratio | 0% |
How did PBIG.F perform over the long term?
See historical performance and comparison